Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
02/03/2023* 08:00 EST Earnings Call Q4 2022 -- -- --
02/03/2023* -- Results Q4 2022 -- 3.49 --
10/25/2022 -- Results Q3 2022 4.77 4.13 15.50%
10/25/2022 08:00 EST Earnings Call Q3 2022 -- -- --
07/20/2022 08:00 EST Earnings Call Q2 2022 -- -- --
07/20/2022 -- Results Q2 2022 5.25 4.07 29.01%
05/03/2022 08:00 EST Earnings Call Q1 2022 -- -- --
05/03/2022 -- Results Q1 2022 3.62 4.36 -17.04%
*Estimated Date/Time

Earnings

Next Report Date 02/03/2023 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 10/25/2022
Beat/Miss Upgrade
Return Since 9.26%
Last FQE 09/30/2022
Next FQE 12/30/2022

Profile

Edit
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
URL http://www.biogen.com
Investor Relations URL https://investors.biogen.com
HQ State/Province Massachusetts
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Large Cap/Value
Next Earnings Release Feb. 03, 2023 (est.)
Last Earnings Release Oct. 25, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0.00%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
-9.75%
-7.43%
21.96%
-5.54%
-1.39%
-17.48%
-2.02%
24.58%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-13.26%
25.37%
-10.37%
17.83%
40.45%
16.15%
31.06%
66.08%
37.51%
7.30%
4.68%
16.13%
25.06%
-6.73%
3.51%
66.74%
-11.00%
32.33%
-32.38%
2.42%
-0.65%
0.53%
28.66%
30.72%
21.36%
5.92%
-41.45%
103.4%
10.58%
32.13%
7.94%
-7.08%
46.34%
As of December 02, 2022.

Profile

Edit
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
URL http://www.biogen.com
Investor Relations URL https://investors.biogen.com
HQ State/Province Massachusetts
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Large Cap/Value
Next Earnings Release Feb. 03, 2023 (est.)
Last Earnings Release Oct. 25, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
VPMCX 2.527B USD 4.20%
IBB 337.96M USD 3.89%
POAGX 235.16M USD 3.49%
MOAT 226.58M USD 3.47%
VHCOX 586.52M USD 3.46%
VPCCX 335.83M USD 3.20%
POGRX 208.97M USD 3.16%
VGHCX 1.409B USD 3.02%
XBI 120.85M USD 1.56%
IWS 91.25M USD 0.68%
IWR 123.01M USD 0.44%
RSP 96.58M USD 0.29%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Nasdaq Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter BIIB Tweets